Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provi...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

Rossi20 Mar. 7 at 3:17 AM

$MNKD It’s really unfortunate,each long shareholder lost average now between $100K-800k from this mess. I am assuming most of you are in the red now. We are bleeding and it’s blood on the street, the Message is right there,then let’s f ing invest heavily in this company once more,because we’re are all know the fundamentals doesn’t lie here. 12 more weeks or sooner and we should be rewarded!!!!!!! F u shorts!!!!

0 · Reply

amsteliam Mar. 7 at 2:07 AM

$MNKD When this drug is approved for kids and this company spends millions marketing it, watch and learn. Anybody here have kids? I do. 4 of them. Ever watch them get injected? And that’s not even Afrezza’s best feature. Need a big and sustained awareness campaign. Will be driven from customer demand. Not doctors subscribing or insurers insuring. Those things will also happen, but because of patient demand. Will take time, but will happen. At least that’s my long standing belief.

2 · Reply

JustAnotherJuggler Mar. 7 at 1:52 AM

$MNKD

0 · Reply

JustAnotherJuggler Mar. 7 at 1:49 AM

$MNKD maybe because you are such a fantastic grifter affizle; you must have scared them. But then again right now there are a lot of institutions buying up MNKD but we won't know what that is until it's filed. Good luck with scaring people.. as a puppet who doesn't use afrezza or an investor in Mannkind. Those characteristics make you an Expert!

0 · Reply

masspd Mar. 7 at 1:42 AM

$MNKD What You Talkin' 'Bout, Willis?

1 · Reply

alexkirchnet85 Mar. 7 at 1:35 AM

$MNKD If the share price would have been higher, the likelihood of paying the convertible note debt with shares instead of cash, would have been greater. If this was an orchestrated move to spare the company further dilution, then kudos to management.

0 · Reply

Affizle Mar. 7 at 1:21 AM

$MNKD Hey JAJ, why did Vanguard reduce their ownership in Mannkind by ~3%? Can you explain this oddity? Oh, and maybe explain why Vanguard holds so many shares? Why is that? Is it because it thinks Mannkind is a screaming buy? If so, why does it not have any of its analysts recommending the stock? Thanks

0 · Reply

JustAnotherJuggler Mar. 7 at 12:19 AM

$MNKD https://www.marketbeat.com/instant-alerts/filing-vanguard-group-inc-has-9468-million-holdings-in-mannkind-corporation-mnkd-2026-03-06/

0 · Reply

Golf365 Mar. 7 at 12:02 AM

$MNKD I sent PM’s on LinkedIn to several Mannkind employees, we shall see if any of them respond. There’s gotta be a rogue employee out there!

0 · Reply

JustAnotherJuggler Mar. 6 at 11:55 PM

$MNKD

0 · Reply

MannKind Announces Settlement of Convertible Senior Notes

Mar 4, 2026, 9:00 AM EST - 2 days ago

MannKind to Participate in Upcoming Investor Conferences

Feb 26, 2026, 4:57 PM EST - 8 days ago

MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 8:00 AM EST - 8 days ago

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 19, 2026, 9:00 AM EST - 15 days ago

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 9:00 AM EST - 16 days ago

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 9, 2026, 6:05 AM EST - 25 days ago

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

Feb 6, 2026, 3:41 AM EST - 4 weeks ago

2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion

Jan 26, 2026, 6:05 AM EST - 5 weeks ago

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Jan 15, 2026, 12:30 PM EST - 7 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 5

HRL HUT IDXX IONQ KDK

Jan 12, 2026, 3:57 PM EST - 7 weeks ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN NVDA OMC UTHR

Jan 8, 2026, 8:05 AM EST - 2 months ago

MannKind Provides Business Updates and 2026 Growth Drivers

Dec 23, 2025, 8:05 AM EST - 2 months ago

MannKind Shares FUROSCIX® Business Updates

Dec 3, 2025, 11:46 AM EST - 3 months ago

MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients

Dec 1, 2025, 8:05 AM EST - 3 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Nov 11, 2025, 4:05 PM EST - 4 months ago

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 10, 2025, 1:21 PM EST - 4 months ago

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript

Nov 10, 2025, 8:00 AM EST - 4 months ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 6, 2025, 9:00 AM EST - 4 months ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 5, 2025, 3:51 PM EST - 4 months ago

MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:00 AM EST - 4 months ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 29, 2025, 4:05 PM EDT - 4 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 15, 2025, 12:55 PM EDT - 5 months ago

MannKind: Durable Cash Engine, Optional Catalysts Pending

Oct 13, 2025, 8:05 AM EDT - 5 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 7, 2025, 9:02 AM EDT - 5 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Sep 29, 2025, 6:05 AM EDT - 5 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 16, 2025, 12:17 PM EDT - 6 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Sep 10, 2025, 7:30 PM EDT - 6 months ago

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 6 months ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 6 months ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 6 months ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 6 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 25, 2025, 1:57 PM EDT - 6 months ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 6 months ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 7 months ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 7 months ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 7 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 7 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 7 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 9 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 9 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 10 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 10 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 10 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 10 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 11 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 11 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 1 year ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 1 year ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 1 year ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Rossi20 Mar. 7 at 3:17 AM

0 · Reply

amsteliam Mar. 7 at 2:07 AM

2 · Reply

JustAnotherJuggler Mar. 7 at 1:52 AM

$MNKD

0 · Reply

JustAnotherJuggler Mar. 7 at 1:49 AM

0 · Reply

masspd Mar. 7 at 1:42 AM

$MNKD What You Talkin' 'Bout, Willis?

1 · Reply

alexkirchnet85 Mar. 7 at 1:35 AM

0 · Reply

Affizle Mar. 7 at 1:21 AM

0 · Reply

JustAnotherJuggler Mar. 7 at 12:19 AM

$MNKD https://www.marketbeat.com/instant-alerts/filing-vanguard-group-inc-has-9468-million-holdings-in-mannkind-corporation-mnkd-2026-03-06/

0 · Reply

Golf365 Mar. 7 at 12:02 AM

$MNKD I sent PM’s on LinkedIn to several Mannkind employees, we shall see if any of them respond. There’s gotta be a rogue employee out there!

0 · Reply

JustAnotherJuggler Mar. 6 at 11:55 PM

$MNKD

0 · Reply

Golf365 Mar. 6 at 11:49 PM

$MNKD Michael Castagna has nonchalantly decimated years of gains from Mannkind shareholders, and he acts like nothing has happened.

0 · Reply

homo Mar. 6 at 11:31 PM

$MNKD 3/1 Form 4's

1 · Reply

kevinmik Mar. 6 at 11:11 PM

$MNKD 3rd time is the charm. Blackstone taking equity stake in Mannkind, not Blackrock who already own shares in Mannkind to the tune of 7% ownership.

0 · Reply

kevinmik Mar. 6 at 11:01 PM

$MNKD Correction to my earlier post today. It should have said wonder if Blackstone will take an equity stake in Mannkind and not Blackstone which I posted in my prior post. Blackstone has extended Mannkind over $500 million in lending with the bulk going to puchase scPharmaceutical and they are also providing advisory service to Mannkind. They now may want to take an equity stake in Mannkind to help them maximize the full value of the company and get an M&A deal done.

0 · Reply

Theman33 Mar. 6 at 10:58 PM

$MNKD Well.. no reversal today..maybe Monday.. this thing is barely even showing a pulse at this point .. kinda scary

0 · Reply

Kool_Aid_Mann Mar. 6 at 10:43 PM

$MNKD What a horrendous disaster of a year 2025 turned out to be for MNKD. The Q4 ER is hands down the worst earnings we have ever had. Analysts had predicted that we'd be doing 0.10 EPS per quarter. Why they went on a spending spree if they knew UT was pulling out is a mystery. Despite doing $111M in revenue, we reported a -0.05 EPS, giving us Q1 .04, Q2 .00, Q3 .03, Q4 -.05 = 2025 EPS =.02. With a 30 P/E that gives us a fair value of 0.60 share price, and that is WITH the UTHR revenue that they will be pulling out. The sg&a costs for furoscix commercialization rose to higher than the planned revenue. This is sinking, because their budget is a total disaster. They either need to learn how to balance their budget or we in in for more massive dilution and another reverse split. #FireThemAll

0 · Reply

grampslol Mar. 6 at 10:37 PM

$MNKD Black Box Label

0 · Reply

bigskyliving Mar. 6 at 10:35 PM

$MNKD Had to pull away from this disaster. I see the volume was well over 9 million shares. I also see no insider buying whatsoever. Way to go M.C. !!!

1 · Reply

Nakom Mar. 6 at 10:32 PM

$MNKD Isperse will be MNKD savior. It can do the heavy lifting.

0 · Reply

YolitheDolly Mar. 6 at 10:24 PM

$MNKD Remember when LQDA dipped down to about $5 and the CEO bought a ton of shares to show he was confident the company was solvent and on the right track. Meanwhile, Mike sells all the free shares he gets from us.

1 · Reply

JumboMike Mar. 6 at 10:24 PM

$MNKD the one thing I don't want to hear on this board is I'm way up on MNKDand bought at $1 BS. Just sickening how these people would say you bought at the wrong time. No clue sherlock nobody bought at the right time with a 1-5 reverse split that makes is .53.

0 · Reply

Affizle Mar. 6 at 10:23 PM

$MNKD I don't know about you guys, but I am excited to hear Mike Castagna tell his investors how undervalued his company is next week during his attendance at both investor conferences on the 10th and 11th in Miami. I emailed him wishing him luck, to enjoy the mid 80's weather and smoke a few nice cigars in honor of his loyal retail investors! LOLZ!

0 · Reply

Market Cap	871.92M
Revenue (ttm)	348.97M
Net Income (ttm)	5.86M
EPS (ttm)	N/A
PE Ratio	147.50
Forward PE	52.68
Profit Margin	1.68%
Debt to Equity Ratio	-8.78

Volume	9,441,500
Avg Vol	5,149,020
Day's Range	N/A - N/A
Shares Out	308.10M
Stochastic %K	1%
Beta	0.83
Analysts	Strong Sell
Price Target	$7.50